We are pleased to welcome Canale Communications, an award-winning San Diego-based strategic communications agency, providing corporate communications, public relations, investor relations, and creative services to life sciences companies including biotech, biopharma, digital health and genomics. CanaleComm will join Ashfield Healthcare Communications, UDG Healthcare’s global agency network that works with clients at the intersections of science, data, and creativity to commercialise molecules, markets, and brands.
Founded in 2010, CanaleComm employs a team of nearly 30 experts who intimately understand the life science industry landscape. The team is uniquely equipped to translate their clients’ business objectives into communications strategy that builds reputation, enhances visibility, and captivates the audiences that matter most. The company has worked with over 300 biotech, medical device, digital health, and pharmaceutical companies.
Commenting on the acquisition, Founder and CEO Carin Canale-Theakston said: “The acquisition of CanaleComm by UDG Healthcare and the joining of forces with Ashfield Healthcare Communications’ network is the ideal platform as we look to grow a more robust service offering for our clients. UDG Healthcare’s focus on life sciences, complementary offering, and strong employee-first culture were all extremely attractive to CanaleComm. We are looking forward to being able to continue the strong growth trajectory that we have been on over the last nine years and being part of the broader UDG Healthcare family.”
The acquisition continues to expand Ashfield Healthcare Communications’ service offering, capabilities, and client base by providing corporate communications, public relations, investor relations, and creative services to biotech and life sciences companies at virtually every stage of development.
“We are thrilled CanaleComm has joined Ashfield Healthcare Communications,” commented Matt Jacobson, Executive Director of Ashfield Healthcare Communications. “They bring a distinct and highly complementary service offering for our healthcare and life sciences clients and further strengthen our U.S. footprint especially in the west coast biotech industry.”